Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00854
|
|||||
Drug Name |
Nandrolone
|
|||||
Synonyms |
(17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one; Decadura; Decadura (TN); Durabolin (TN); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estrenolone; LT03330030; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum; Nandrolonum [INN-Latin]; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; U 2410
|
|||||
Drug Type |
Small molecular drug
|
|||||
Therapeutic Class |
Anabolic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C18H26O2
|
|||||
Canonical SMILES |
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34
|
|||||
InChI |
InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
|
|||||
InChIKey |
NPAGDVCDWIYMMC-IZPLOLCNSA-N
|
|||||
CAS Number |
CAS 434-22-0
|
|||||
Pharmaceutical Properties | Molecular Weight | 274.4 | Topological Polar Surface Area | 37.3 | ||
Heavy Atom Count | 20 | Rotatable Bond Count | 0 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
XLogP |
2.6
|
|||||
PubChem CID | ||||||
ChEBI ID |
ChEBI:7466
|
|||||
TTD Drug ID |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.